These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Fukuzawa T; Sampei Z; Haraya K; Ruike Y; Shida-Kawazoe M; Shimizu Y; Gan SW; Irie M; Tsuboi Y; Tai H; Sakiyama T; Sakamoto A; Ishii S; Maeda A; Iwayanagi Y; Shibahara N; Shibuya M; Nakamura G; Nambu T; Hayasaka A; Mimoto F; Okura Y; Hori Y; Habu K; Wada M; Miura T; Tachibana T; Honda K; Tsunoda H; Kitazawa T; Kawabe Y; Igawa T; Hattori K; Nezu J Sci Rep; 2017 Apr; 7(1):1080. PubMed ID: 28439081 [TBL] [Abstract][Full Text] [Related]
5. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688 [TBL] [Abstract][Full Text] [Related]
6. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308 [TBL] [Abstract][Full Text] [Related]
8. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases. Fukuzawa T; Nezu J Curr Med Chem; 2020; 27(25):4157-4164. PubMed ID: 31622197 [TBL] [Abstract][Full Text] [Related]
9. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Gurbaxani B; Dostalek M; Gardner I Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Luzzatto L; Gianfaldoni G Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130 [TBL] [Abstract][Full Text] [Related]
11. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data. Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379 [TBL] [Abstract][Full Text] [Related]
12. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301 [TBL] [Abstract][Full Text] [Related]
13. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway. Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791 [TBL] [Abstract][Full Text] [Related]
14. A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target. Watanabe H; Shibuya M; Shibahara N; Ruike Y; Sampei Z; Haraya K; Tachibana T; Wakabayashi T; Sakamoto A; Tsunoda H; Murao N AAPS J; 2021 Jan; 23(1):21. PubMed ID: 33415498 [TBL] [Abstract][Full Text] [Related]
15. Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Zelek WM; Taylor PR; Morgan BP Immunology; 2019 Aug; 157(4):283-295. PubMed ID: 31120547 [TBL] [Abstract][Full Text] [Related]
16. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W MAbs; 2015; 7(5):912-21. PubMed ID: 26018774 [TBL] [Abstract][Full Text] [Related]
17. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424 [TBL] [Abstract][Full Text] [Related]
18. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment. Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Risitano AM; Marotta S Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521 [TBL] [Abstract][Full Text] [Related]
20. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]